|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FUZ |
Gene summary for FUZ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FUZ | Gene ID | 80199 |
| Gene name | fuzzy planar cell polarity protein | |
| Gene Alias | CPLANE3 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q9BT04 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80199 | FUZ | LZE24T | Human | Esophagus | ESCC | 1.12e-12 | 2.43e-01 | 0.0596 |
| 80199 | FUZ | P2T-E | Human | Esophagus | ESCC | 1.31e-04 | 9.70e-02 | 0.1177 |
| 80199 | FUZ | P4T-E | Human | Esophagus | ESCC | 2.35e-10 | 2.62e-01 | 0.1323 |
| 80199 | FUZ | P8T-E | Human | Esophagus | ESCC | 2.61e-25 | 4.13e-01 | 0.0889 |
| 80199 | FUZ | P10T-E | Human | Esophagus | ESCC | 2.28e-19 | 2.87e-01 | 0.116 |
| 80199 | FUZ | P11T-E | Human | Esophagus | ESCC | 8.40e-05 | 2.10e-01 | 0.1426 |
| 80199 | FUZ | P12T-E | Human | Esophagus | ESCC | 6.98e-22 | 3.25e-01 | 0.1122 |
| 80199 | FUZ | P15T-E | Human | Esophagus | ESCC | 9.22e-12 | 1.39e-01 | 0.1149 |
| 80199 | FUZ | P16T-E | Human | Esophagus | ESCC | 2.16e-14 | 2.76e-01 | 0.1153 |
| 80199 | FUZ | P17T-E | Human | Esophagus | ESCC | 7.04e-04 | 1.80e-01 | 0.1278 |
| 80199 | FUZ | P19T-E | Human | Esophagus | ESCC | 3.01e-09 | 3.92e-01 | 0.1662 |
| 80199 | FUZ | P20T-E | Human | Esophagus | ESCC | 3.30e-05 | 6.59e-02 | 0.1124 |
| 80199 | FUZ | P21T-E | Human | Esophagus | ESCC | 1.73e-04 | 6.65e-02 | 0.1617 |
| 80199 | FUZ | P22T-E | Human | Esophagus | ESCC | 2.55e-12 | 1.31e-01 | 0.1236 |
| 80199 | FUZ | P26T-E | Human | Esophagus | ESCC | 3.20e-12 | 2.43e-01 | 0.1276 |
| 80199 | FUZ | P27T-E | Human | Esophagus | ESCC | 6.95e-15 | 2.43e-01 | 0.1055 |
| 80199 | FUZ | P28T-E | Human | Esophagus | ESCC | 1.09e-03 | 7.01e-02 | 0.1149 |
| 80199 | FUZ | P30T-E | Human | Esophagus | ESCC | 8.21e-11 | 3.26e-01 | 0.137 |
| 80199 | FUZ | P31T-E | Human | Esophagus | ESCC | 3.29e-14 | 3.23e-01 | 0.1251 |
| 80199 | FUZ | P32T-E | Human | Esophagus | ESCC | 1.03e-07 | 1.54e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:000184115 | Esophagus | ESCC | neural tube formation | 75/8552 | 102/18723 | 9.68e-09 | 1.95e-07 | 75 |
| GO:000184314 | Esophagus | ESCC | neural tube closure | 66/8552 | 88/18723 | 1.98e-08 | 3.82e-07 | 66 |
| GO:001402014 | Esophagus | ESCC | primary neural tube formation | 69/8552 | 94/18723 | 4.22e-08 | 7.76e-07 | 69 |
| GO:006060614 | Esophagus | ESCC | tube closure | 66/8552 | 89/18723 | 4.24e-08 | 7.76e-07 | 66 |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:00219159 | Esophagus | ESCC | neural tube development | 101/8552 | 152/18723 | 1.78e-07 | 2.79e-06 | 101 |
| GO:00163316 | Esophagus | ESCC | morphogenesis of embryonic epithelium | 98/8552 | 147/18723 | 2.12e-07 | 3.27e-06 | 98 |
| GO:000183814 | Esophagus | ESCC | embryonic epithelial tube formation | 83/8552 | 121/18723 | 2.78e-07 | 4.08e-06 | 83 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
| GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
| GO:006082817 | Esophagus | ESCC | regulation of canonical Wnt signaling pathway | 153/8552 | 253/18723 | 1.38e-06 | 1.67e-05 | 153 |
| GO:003514815 | Esophagus | ESCC | tube formation | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
| GO:00721759 | Esophagus | ESCC | epithelial tube formation | 86/8552 | 132/18723 | 4.81e-06 | 5.10e-05 | 86 |
| GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:00017387 | Esophagus | ESCC | morphogenesis of a polarized epithelium | 63/8552 | 94/18723 | 2.34e-05 | 2.00e-04 | 63 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FUZ | SNV | Missense_Mutation | c.143N>A | p.Gly48Glu | p.G48E | Q9BT04 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A26Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
| FUZ | insertion | Frame_Shift_Ins | novel | c.326_327insCACAGGTGAGGACTATCCCATTACCTCATCATTCCCATATTACAGA | p.Val110ThrfsTer19 | p.V110Tfs*19 | Q9BT04 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| FUZ | SNV | Missense_Mutation | c.566N>T | p.Ala189Val | p.A189V | Q9BT04 | protein_coding | tolerated(1) | benign(0.007) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FUZ | SNV | Missense_Mutation | rs779762408 | c.1166N>T | p.Arg389Leu | p.R389L | Q9BT04 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FUZ | SNV | Missense_Mutation | c.596N>T | p.Thr199Met | p.T199M | Q9BT04 | protein_coding | tolerated(0.27) | benign(0.007) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FUZ | SNV | Missense_Mutation | c.983N>A | p.Arg328His | p.R328H | Q9BT04 | protein_coding | tolerated(0.05) | benign(0.007) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
| FUZ | SNV | Missense_Mutation | novel | c.457G>A | p.Asp153Asn | p.D153N | Q9BT04 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FUZ | SNV | Missense_Mutation | novel | c.1169N>C | p.Leu390Pro | p.L390P | Q9BT04 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| FUZ | SNV | Missense_Mutation | novel | c.1019C>T | p.Thr340Met | p.T340M | Q9BT04 | protein_coding | tolerated(0.19) | benign(0.022) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| FUZ | SNV | Missense_Mutation | novel | c.440A>G | p.Asp147Gly | p.D147G | Q9BT04 | protein_coding | deleterious(0.04) | possibly_damaging(0.894) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |